Long-term rotational stability and visual outcomes of a single-piece hydrophilic acrylic toric IOL

Session Details

Session Title: Pseudophakic IOLs: Toric II

Session Date/Time: Sunday 11/09/2016 | 16:00-18:00

Paper Time: 17:22

Venue: Auditorium C6

First Author: : P.Jirak AUSTRIA

Co Author(s): :    B. Gyoengyoessy   U. Schönherr                 

Abstract Details

Purpose:

To evaluate the rotational stability and visual outcomes of a single-piece hydrophilic acrylic toric IOL over a 1.5-year follow-up period.

Setting:

Konventhospital der Barmherzigen Brüder, Linz, Austria

Methods:

Forty eyes of 26 cataract patients (mean age: 72.8 ± 7.9 years) with pre-existing corneal astigmatism of 1.0 to 2.6 D were enrolled in the study. Mean axial length was 23.17 ± 0.88 mm. The rotational stability of the Torica-aA IOL (HumanOptics) was evaluated using retroillumination photographs taken within 24 h after surgery and 1 week, 6 months and 1.5 years postoperatively. Other main study outcomes were assessed 6 months and 1.5 years postoperatively and included subjective refraction, keratometry, uncorrected and corrected distance visual acuity (UDVA, CDVA). The efficacy of the astigmatism correction was evaluated by vector analysis.

Results:

There was no significant change in the parameters evaluated between the 6 months and 1.5 years follow-ups. At last visit, mean absolute IOL misalignment was 2.03 ± 2.15° (range 0.00 to 7.50°). Mean residual refractive cylinder was -0.60 ± 0.41 D. There was a significant reduction in the magnitude of the J0 vector postoperatively (p<0.0001) with a mean absolute change of 0.76 ± 0.40 D. The mean J45 vector was close to zero preoperatively and postoperatively. Mean monocular UDVA and CDVA was 0.09 ± 0.12 logMAR and -0.01 ± 0.12 logMAR, respectively. No treatment with Nd:YAG laser was required.

Conclusions:

Implantation of the Torica-aA IOL was safe and effective in reducing low to moderate pre-existing corneal astigmatism and provided good rotational stability and visual outcomes over a 1.5 years follow-up period.

Financial Disclosure:

NONE